Gleneagles Hospital Introduces Blood Test Screening for 50 Cancer Types
SingTao · 1 SOURCESabout 1 hour ago2 MIN
Summary
Gleneagles Hospital Hong Kong has introduced LucenceINSIGHT, a novel cancer screening technology that can detect up to 50 cancer types through a single blood test, becoming one of the first private hospitals in Hong Kong to offer this service. The technology, developed by Lucence with a claimed specificity of 99% and sensitivity of 80.9%, aims to address limitations of earlier multi-cancer early detection tests that produced higher false positive rates. Hospital CEO Eric Tsang Hing-lian highlighted that the non-invasive approach could encourage more patients to participate in screening, while the company's founder, oncologist Dr. Chan Man Hon, noted that early diagnosis can improve five-year survival rates by up to four times.
Key Points
- Gleneagles Hospital Hong Kong adopted LucenceINSIGHT technology, capable of screening 50 cancer types including lung, breast, and colorectal cancers with one blood draw .
- The new test achieves 99% specificity, 80.9% sensitivity, and 87.7% accuracy in locating tumor origins, significantly outperforming earlier MCED technology .
- Hospital CEO Eric Tsang Hing-lian stated the blood-based test avoids invasive procedures, potentially increasing patient willingness to undergo screening .
- Dr. Chan Man Hon, founder of Lucence, indicated that early-stage cancer detection (stages 1-2) yields 40-60% sensitivity, with particularly high rates for lung and rectal cancers .
- Service packages start from HK$4,000 to over HK$10,000, offering personalized plans with six common cancers as the base and options to add three more .
Why It Matters
The introduction of this advanced blood-based cancer screening at Gleneagles represents a significant shift toward preventive healthcare in Hong Kong, potentially enabling earlier intervention when cancer is most treatable. By reducing the barriers of invasive procedures and lengthy diagnostic processes, the technology could increase screening participation rates and ultimately decrease late-stage cancer diagnoses that burden both patients and the healthcare system .
The introduction of this advanced blood-based cancer screening at Gleneagles represents a significant shift toward preventive healthcare in Hong Kong, potentially enabling earlier intervention when cancer is most treatable. By reducing the barriers of invasive procedures and lengthy diagnostic processes, the technology could increase screening participation rates and ultimately decrease late-stage cancer diagnoses that burden both patients and the healthcare system .